Asset
Adimanebart
argenx SE American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05670704 | phase1 | completed | 2023-02-21 | 2024-08-08 | argenx | A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants |
| NCT06436742 | phase1 | active_not_recruiting | 2024-09-24 | 2027-08-24 | argenx | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) |
| NCT06441682 | phase2 | active_not_recruiting | 2024-10-23 | 2026-08-01 | argenx | A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) |
FDA applications (0)
This company has no applications containing this asset.